Workflow
TMSP(600671)
icon
Search documents
天目药业: 杭州天目山药业股份有限公司信息披露暂缓与豁免管理制度(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
Core Points - The document outlines the information disclosure deferral and exemption management system for Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd, aiming to ensure compliance with legal obligations and protect investors' rights [1][2][3] Group 1: Information Disclosure Management - The company must adhere to various laws and regulations, including the Company Law and Securities Law, while managing information disclosure deferrals and exemptions [1] - Information that involves state secrets or commercial secrets must not be disclosed through any means, including investor interactions and press releases [2][3] - The company can defer or exempt disclosure of information that may lead to unfair competition or harm to its interests or those of others [3][4] Group 2: Conditions for Disclosure Deferral - If the reasons for deferral or exemption are no longer valid, or if the information becomes difficult to keep confidential, timely disclosure is required [5][6] - The definition of commercial secrets includes information that is not publicly known, provides economic benefits, and is protected by confidentiality measures [6][7] Group 3: Internal Review Procedures - A formal internal review process is required for deferring or exempting information disclosure, involving the board secretary and the company chairman [5][6] - The company must maintain records of all deferral and exemption requests for a minimum of 10 years [6] Group 4: Reporting Obligations - After the announcement of annual, semi-annual, or quarterly reports, the company must submit relevant documentation regarding deferred or exempted disclosures to the Zhejiang Securities Regulatory Bureau and the Shanghai Stock Exchange within ten days [6][7] - Any amendments to the system must comply with the latest laws and regulations, and the board is responsible for its formulation and revision [7]
天目药业: 杭州天目山药业股份有限公司防范大股东及其关联方资金占用专项制度(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
杭州天目山药业股份有限公司防范大股东及其关联方资金占用制度 杭州天目山药业股份有限公司 防范大股东及其关联方资金占用专项制度 (2025年8月修订) 第一章 总则 第一条 为了防止大股东、控股股东或实际控制人及其关联方(以 下简称"大股东及其关联方")占用杭州天目山药业股份有限公司 (以下简称"公司")资金,建立防范的长效机制,杜绝大股东及其 关联方资金占用行为的发生,维护公司的独立性,根据《中华人民共 和国公司法》(以下简称"《公司法》")、《中华人民共和国证券 法》《上市公司自律监管指引第8号——上市公司资金往来、对外担保 的监管要求》《上市公司治理准则》、《上海证券交易所股票上市规 则》(以下简称"《股票上市规则》")、《上海证券交易所上市公 司自律监管指引第1号——规范运作》(以下简称"《规范运作》") 和《杭州天目山药业股份有限公司章程》(以下简称"《公司章 程》")以及国家规定的相关法律、法规和规范性文件的有关规定, 制定本制度。 第二条 公司董事和高级管理人员对维护公司资金安全有法定义务。 第三条 本制度所称资金占用包括但不限于:经营性资金占用和非 经营性资金占用。经营性资金占用是指大股东及其关 ...
天目药业: 杭州天目山药业股份有限公司董事会秘书工作制度(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
杭州天目山药业股份有限公司董事会秘书工作制度 杭州天目山药业股份有限公司 董事会秘书工作制度 (2025 年 8 月修订) 第一章 总 则 第一条 为明确杭州天目山药业股份有限公司(以下简称"公司") 董事会秘书责任,提高工作效率,依据《中华人民共和国公司法》 (以下简称"《公司法》")、《中华人民共和国证券法》《上海证 券交易所股票上市规则》(以下简称"《股票上市规则》")等法 律、法规和其他规范性文件及《杭州天目山药业股份有限公司章程》 (以下简称"《公司章程》")的有关规定,制定本制度。 第二条 公司董事会秘书为公司高级管理人员。在董事长领导下开 展工作,对公司和董事会负责。依据《公司章程》和《股票上市规 则》赋予的职权开展工作和履行职责。 董事会秘书是公司与证券交易所之间的指定联络人。 第二章 任职资格 第三条 担任董事会秘书,应当具备以下条件: (一)具有良好的职业道德和个人品质; (二)具备履行职责所必须的财务、管理、法律等专业知识; (三)具备履行职责所必须的工作经验。 (四)曾被中国证监会采取不得担任公司董事、高级管理人员的市 场禁入措施; (五)中国证监会或证券交易所认定不适合担任董事会秘书 ...
天目药业: 杭州天目山药业股份有限公司信息披露管理办法(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
Core Viewpoint - The document outlines the information disclosure management system of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of the company and its investors [1][2]. Group 1: General Principles - The information disclosure obligations must be fulfilled timely and should be true, accurate, complete, and fair, avoiding any false records or misleading statements [2][3]. - The system applies to various personnel including the board of directors, senior management, and major shareholders [2][3]. - The company must ensure that all disclosed information is made available to all investors simultaneously, without any selective disclosure [4][5]. Group 2: Disclosure Content - The company is required to disclose periodic reports, including annual, semi-annual, and quarterly reports, as well as other significant documents like prospectuses and acquisition reports [6][7]. - Annual reports must be disclosed within four months after the fiscal year-end, while semi-annual reports should be disclosed within two months after the first half of the fiscal year [7][8]. - The content of the annual report includes basic company information, major financial data, stock and bond issuance details, and significant events affecting the company [8][9]. Group 3: Responsibilities and Management - The board of directors is responsible for overseeing the information disclosure process, with the chairman being the primary responsible person [17][18]. - The board secretary plays a crucial role in coordinating the information disclosure activities and ensuring compliance with relevant regulations [17][18]. - All departments and subsidiaries must report significant information to the board secretary promptly to ensure timely disclosure [21][22]. Group 4: Compliance and Training - The company must provide training on information disclosure responsibilities to relevant personnel to ensure compliance with regulations [25][26]. - Any violations of the disclosure obligations may lead to administrative and economic penalties for responsible individuals [26][27]. - The company must maintain communication with regulatory bodies and ensure that all disclosures are in line with legal requirements [25][28].
天目药业: 杭州天目山药业股份有限公司战略委员会工作细则(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
Core Viewpoint - The article outlines the working rules and responsibilities of the Strategic Committee of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd., emphasizing the importance of enhancing corporate governance and decision-making processes for long-term strategic development [1][2]. Group 1: General Provisions - The Strategic Committee is established to improve corporate governance and ensure the rationality of long-term development strategies and plans [1]. - The committee is accountable to the Board of Directors and operates under the guidelines of the company's articles of association and relevant regulations [1][2]. Group 2: Composition - The committee consists of 3 to 5 directors, including at least one expert in management, law, or product development [2]. - The committee members are nominated by the chairman or independent directors and elected by the Board [2]. Group 3: Responsibilities and Authority - The main responsibilities include researching long-term development strategies, major investments, sustainable development, and ESG governance [4]. - The committee evaluates internal and external environmental changes affecting the company's strategic position and market strategies [4]. - It also reviews major investment and financing plans, assesses significant ESG matters, and guides subsidiaries in implementing strategic and risk management policies [4][5]. Group 4: Work Procedures - The committee operates as a non-full-time body, conducting regular and ad-hoc meetings as needed [5]. - Relevant departments are responsible for providing timely and accurate information to support the committee's work [5][6]. Group 5: Meeting Rules - Meetings require the presence of at least two-thirds of the members to be valid, and decisions are made by a majority vote [6][7]. - The committee can invite external experts for professional opinions, with costs covered by the company [7][8].
天目药业: 杭州天目山药业股份有限公司薪酬与考核委员会工作细则(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
杭州天目山药业股份有限公司董事会薪酬与考核委员会工作细则 杭州天目山药业股份有限公司 董事会薪酬与考核委员会工作细则 (2025 年 8 月修订) 第一章 总则 第一条 为进一步建立健全杭州天目山药业股份有限公司(以下 简称"公司")董事及高级管理人员的考核和薪酬管理制度,完善公 司治理结构,根据《中华人民共和国公司法》《上市公司治理准则》 《杭州天目山药业股份有限公司公司章程》 (以下简称" 《公司章程》 ") 及有关规定,公司特设立董事会薪酬与考核委员会,并制定本工作细 则。 第二条 薪酬与考核委员会是董事会设立的专门工作机构,主要 负责制定公司董事及高级管理人员的考核标准并进行考核;负责制 定、审查公司董事及高级管理人员的薪酬政策与方案,对董事会负责。 第三条 本细则所称董事是指在本公司领取薪酬的董事长、董事, 高级管理人员是指董事会聘任的总经理、副总经理、董事会秘书、财 务总监及《公司章程》中规定的高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由三名董事组成,独立董事占多 数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董 事或者全体董事的三分之一提名,并由董事会选举产生。 ...
天目药业: 杭州天目山药业股份有限公司独立董事制度(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
第一条 为进一步完善杭州天目山药业股份有限公司(以下简称 "公司")的法人治理结构,规范独立董事行为,充分发挥独立董事 在上市公司治理中的作用,促进提高上市公司质量,维护公司的整体 利益及中小投资者的合法利益,根据《中华人民共和国公司法》《中 华人民共和国证券法》《国务院办公厅关于上市公司独立董事制度改 革的意见》 《上市公司独立董事管理办法》 《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等法律、法规及规范性文件及《杭 州天目山药业股份有限公司章程》 (以下简称" 《公司章程》" )有关规 杭州天目山药业股份有限公司独立董事制度 杭州天目山药业股份有限公司 独立董事制度 (2025 年 8 月修订) 第一章 总 则 定,结合公司实际情况,特制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务,并与 其所受聘的公司及其主要股东、实际控制人不存在直接或者间接利害 关系,或者其他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责,不受公司及其主要股东、实际控制 人等单位或者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务,应当 按照法律、行政法规、中国证券 ...
天目药业: 杭州天目山药业股份有限公司章程(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
Group 1 - The company, Hangzhou Tian-Mu-Shan Pharmaceutical Co., Ltd., was established as a pilot unit for state-owned enterprise reform in October 1989 and has undergone several regulatory updates since then [2][3][4] - The registered capital of the company is RMB 121.78 million, and it operates as a permanent joint-stock company [4][5] - The company aims to develop a modern enterprise group with first-class economic benefits and products, focusing on pharmaceutical production and diversified development [3][4] Group 2 - The company has established a party organization to play a political core role and provide political guidance in its development [2] - The company’s business scope includes the production of various pharmaceutical forms, health foods, medical devices, and cosmetics, among others [3][4] Group 3 - The company issues shares in the form of stocks, with each share having a face value of RMB 1 [4][5] - The total number of shares issued by the company is 121,778,885, all of which are ordinary shares [4][5] Group 4 - The company is prohibited from providing financial assistance for others to acquire its shares, except under specific circumstances approved by the shareholders' meeting [5][6] - The company can reduce its registered capital following legal procedures and shareholder approval [6][7] Group 5 - The company’s shareholders have rights to dividends, voting, and other benefits proportional to their shareholdings [10][11] - Shareholders holding more than 5% of the shares must declare their holdings and any changes [8][9] Group 6 - The company’s shareholders' meeting is the authority of the company, responsible for electing directors, approving financial reports, and making significant corporate decisions [18][19] - The company must hold an annual shareholders' meeting within six months after the end of the previous fiscal year [21][22]
天目药业: 杭州天目山药业股份有限公司董事会审计委员会工作细则(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
Core Points - The article outlines the work rules of the Audit Committee of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd, emphasizing the importance of internal control and financial oversight [1][2][3] Group 1: General Provisions - The Audit Committee is established to enhance corporate governance and ensure effective supervision of financial activities [1] - The committee operates independently and reports directly to the Board of Directors [1][2] Group 2: Composition of the Committee - The committee consists of at least three directors who are not senior management, with a majority being independent directors, including at least one accounting professional [2] - The term of committee members aligns with that of the Board, with independent directors limited to a maximum of six consecutive years [2][3] Group 3: Responsibilities and Authority - The main responsibilities include supervising external audit work, evaluating internal audit processes, and reviewing financial information [3][4] - The committee must approve significant financial disclosures and the hiring or dismissal of external auditors before submission to the Board [3][4] Group 4: Internal Audit Oversight - The committee supervises the internal audit department, ensuring it operates effectively and reports directly to the committee [9][10] - Internal audit findings must be reported to the committee, which also evaluates the effectiveness of internal controls [10][11] Group 5: Meeting Procedures - The committee holds regular meetings at least quarterly, with special meetings convened as necessary [28][29] - Decisions require a majority vote from attending members, and detailed records of meetings must be maintained [30][31] Group 6: Reporting and Evaluation - The committee is required to submit annual reports on its activities and evaluations of external auditors to the Board [15][16] - It also has the authority to propose the convening of extraordinary shareholder meetings when necessary [6][7]
天目药业: 杭州天目山药业股份有限公司股东会议事规则(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
General Provisions - The rules are established to regulate the behavior of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. and ensure shareholders can exercise their rights according to relevant laws and regulations [1][2] - The company must strictly follow legal and regulatory requirements when convening shareholder meetings [1][3] Shareholder Meeting Authority - The shareholder meeting is the company's authority body, responsible for electing and replacing directors, approving reports, and making decisions on profit distribution, capital changes, and other significant matters [1][3] - The company must ensure that shareholders can exercise their rights within the scope defined by the Company Law and the Articles of Association [1][3] Types of Shareholder Meetings - There are annual and temporary shareholder meetings, with annual meetings held within six months after the end of the previous fiscal year [4][5] - Temporary meetings must be convened within two months under specific circumstances, such as insufficient directors or significant losses [5][6] Proposal and Notification - Shareholders holding 1% or more of shares can propose agenda items for the shareholder meeting, and proposals must be submitted in writing [10][11] - Notifications for meetings must be made at least 20 days in advance for annual meetings and 15 days for temporary meetings [18][19] Voting and Decision-Making - Voting can be conducted in person or through authorized representatives, and the company must ensure a fair voting process [12][13] - The results of the voting must be announced immediately after the meeting, and detailed records must be kept for future reference [42][43] Legal Compliance - The rules must comply with national laws and regulations, and any violations can lead to invalidation of shareholder meeting resolutions [20][21] - The company is responsible for executing resolutions passed in shareholder meetings and must disclose relevant information as required by law [20][21]